A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma
NCT ID: NCT04499339
Last Updated: 2024-04-25
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
38 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-07-22
Study Completion Date
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Multiple myeloma (MM) is a rare hematologic malignancy of aberrant plasma cells.
There is a high and currently unmet medical need for novel, innovative treatment concepts to improve the therapeutic outcome and prognosis of patients suffering from MM.
There is definitive evidence that MM is susceptible to immune-based therapies from pre-clinical investigations and early clinical trials.
CARAMBA-1 is a first-in-human clinical trial of adoptive immunotherapy with autologous signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR)-T cells in patients with advanced MM that have exhausted conventional therapies.
The CARAMBA-1 clinical trial is an open-label, non-randomized, multicenter clinical trial which combines a phase I dose-escalation part with a phase IIa dose-expansion part to assess feasibility, safety and anti-myeloma activity of SLAMF7 CAR-T cells.
The CARAMBA project and the CARAMBA-1 clinical trial are supported by the European Union in the Horizon 2020 research and innovation program.
There is a high and currently unmet medical need for novel, innovative treatment concepts to improve the therapeutic outcome and prognosis of patients suffering from MM.
There is definitive evidence that MM is susceptible to immune-based therapies from pre-clinical investigations and early clinical trials.
CARAMBA-1 is a first-in-human clinical trial of adoptive immunotherapy with autologous signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR)-T cells in patients with advanced MM that have exhausted conventional therapies.
The CARAMBA-1 clinical trial is an open-label, non-randomized, multicenter clinical trial which combines a phase I dose-escalation part with a phase IIa dose-expansion part to assess feasibility, safety and anti-myeloma activity of SLAMF7 CAR-T cells.
The CARAMBA project and the CARAMBA-1 clinical trial are supported by the European Union in the Horizon 2020 research and innovation program.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma
NCT04864522
Multiple Myeloma
WITHDRAWN
PHASE1/PHASE2
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
NCT03000634
Multiple Myeloma
WITHDRAWN
PHASE2
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
NCT00530816
Multiple Myeloma
COMPLETED
PHASE2
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
NCT04035226
Multiple Myeloma
COMPLETED
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
NCT05669989
Plasma Cell Myeloma
ACTIVE_NOT_RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Multiple myeloma (MM) is a rare hematologic malignancy of aberrant plasma cells.
There is a high and currently unmet medical need for novel, innovative treatment concepts to improve the therapeutic outcome and prognosis of patients suffering from MM.
There is definitive evidence that MM is susceptible to immune-based therapies from pre-clinical investigations and early clinical trials.
CARAMBA-1 is a first-in human clinical trial of adoptive immunotherapy with autologous SLAMF7 CAR-T cells in patients with advanced MM that have exhausted conventional therapies.
The CARAMBA-1 clinical trial is an open-label, non-randomized, multicenter clinical trial which combines a phase I dose-escalation part with a phase IIa dose-expansion part to assess feasibility, safety and anti-myeloma activity of SLAMF7 CAR-T cells.
SLAMF7 CAR-T cells are manufactured using virus-free gene-transfer using the Sleeping Beauty transposon system.
The CAR-T cell product is formulated to contain equal proportions of CD8 cytotoxic and CD4 helper SLAMF7 CAR-T cells.
The CARAMBA project and the CARAMBA-1 clinical trial are supported by the European Union in the Horizon 2020 research and innovation program.
There is a high and currently unmet medical need for novel, innovative treatment concepts to improve the therapeutic outcome and prognosis of patients suffering from MM.
There is definitive evidence that MM is susceptible to immune-based therapies from pre-clinical investigations and early clinical trials.
CARAMBA-1 is a first-in human clinical trial of adoptive immunotherapy with autologous SLAMF7 CAR-T cells in patients with advanced MM that have exhausted conventional therapies.
The CARAMBA-1 clinical trial is an open-label, non-randomized, multicenter clinical trial which combines a phase I dose-escalation part with a phase IIa dose-expansion part to assess feasibility, safety and anti-myeloma activity of SLAMF7 CAR-T cells.
SLAMF7 CAR-T cells are manufactured using virus-free gene-transfer using the Sleeping Beauty transposon system.
The CAR-T cell product is formulated to contain equal proportions of CD8 cytotoxic and CD4 helper SLAMF7 CAR-T cells.
The CARAMBA project and the CARAMBA-1 clinical trial are supported by the European Union in the Horizon 2020 research and innovation program.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Multiple Myeloma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SEQUENTIAL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All eligible patients
Group Type
EXPERIMENTAL
SLAMF7 CAR-T
Intervention Type
DRUG
Single infusion of autologous SLAMF7 CAR-T cells
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SLAMF7 CAR-T
Single infusion of autologous SLAMF7 CAR-T cells
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Signed informed consent form.
2. Patient is ≥18 years of age.
3. Patient is willing and able to adhere to the protocol requirements.
4. Patient with diagnosis of MM who has been treated with at least 2 prior lines of treatment, including at least one cycle of high-dose chemotherapy with autologous hematopoietic stem cell transplantation if the patient was eligible, and exposure to an immunomodulatory imide drug (e.g. lenalidomide and/or pomalidomide), a proteasome inhibitor, and an anti-CD38 antibody.
(Note: Induction therapy, up to 2 cycles of high-dose chemotherapy with autologous hematopoietic stem cell transplantation, and subsequent consolidation and/or maintenance therapy are considered one line of treatment).
5. At least one of the following subcriteria must be measured in the patient:
* Serum M-protein greater or equal to 0.5 g/dL
* Urine M-protein greater or equal to 200 mg/24 h
* Serum free light chain (FLC) assay: involved FLC level greater or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal
* A biopsy-proven evaluable plasmacytoma
* Bone marrow plasma cells \>10% of total bone marrow cells (\>30% if bone marrow plasma cells are the only marker of measurable disease)
6. Patients previously treated with an anti-SLAMF7 antibody are eligible.
7. Karnofsky performance status ≥60%. If patient has a Karnofsky performance status \<60% (e.g. after a spinal cord injury) but is judged to be medically fit by the investigator, patient is eligible.
8. Female patients of childbearing potential must:
1. have a negative pregnancy test (blood) at screening.
2. either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with, effective measures of contraception without interruption, from screening through 1 year following the investigantional medicinal product (IMP) infusion. A highly effective method of contraception or birth control (failure rate less than 1% per year when used consistently and correctly) must be practiced. The patient should be informed of the potential risks associated with becoming pregnant while enrolled in this clinical trial. Reliable methods for this trial are: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, sexual abstinence or vasectomized sexual partner. Abstinence is only accepted as true abstinence: when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence \[e.g. calendar, ovulation, symptothermal, post-ovulation methods and withdrawal\] are not acceptable methods of contraception.) Postmenopausal (no menses for at least 1 year without alternative medical cause) or surgically sterile female patients (tubal ligation, hysterectomy or bilateral oophorectomy) may be enrolled.
3. Agree to abstain from breast feeding during the study participation and for 1 year after the IMP infusion.
9. Male patients must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential for at least 1 year after IMP infusion, even if he has undergone a successful vasectomy.
2. Patient is ≥18 years of age.
3. Patient is willing and able to adhere to the protocol requirements.
4. Patient with diagnosis of MM who has been treated with at least 2 prior lines of treatment, including at least one cycle of high-dose chemotherapy with autologous hematopoietic stem cell transplantation if the patient was eligible, and exposure to an immunomodulatory imide drug (e.g. lenalidomide and/or pomalidomide), a proteasome inhibitor, and an anti-CD38 antibody.
(Note: Induction therapy, up to 2 cycles of high-dose chemotherapy with autologous hematopoietic stem cell transplantation, and subsequent consolidation and/or maintenance therapy are considered one line of treatment).
5. At least one of the following subcriteria must be measured in the patient:
* Serum M-protein greater or equal to 0.5 g/dL
* Urine M-protein greater or equal to 200 mg/24 h
* Serum free light chain (FLC) assay: involved FLC level greater or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal
* A biopsy-proven evaluable plasmacytoma
* Bone marrow plasma cells \>10% of total bone marrow cells (\>30% if bone marrow plasma cells are the only marker of measurable disease)
6. Patients previously treated with an anti-SLAMF7 antibody are eligible.
7. Karnofsky performance status ≥60%. If patient has a Karnofsky performance status \<60% (e.g. after a spinal cord injury) but is judged to be medically fit by the investigator, patient is eligible.
8. Female patients of childbearing potential must:
1. have a negative pregnancy test (blood) at screening.
2. either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with, effective measures of contraception without interruption, from screening through 1 year following the investigantional medicinal product (IMP) infusion. A highly effective method of contraception or birth control (failure rate less than 1% per year when used consistently and correctly) must be practiced. The patient should be informed of the potential risks associated with becoming pregnant while enrolled in this clinical trial. Reliable methods for this trial are: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, sexual abstinence or vasectomized sexual partner. Abstinence is only accepted as true abstinence: when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence \[e.g. calendar, ovulation, symptothermal, post-ovulation methods and withdrawal\] are not acceptable methods of contraception.) Postmenopausal (no menses for at least 1 year without alternative medical cause) or surgically sterile female patients (tubal ligation, hysterectomy or bilateral oophorectomy) may be enrolled.
3. Agree to abstain from breast feeding during the study participation and for 1 year after the IMP infusion.
9. Male patients must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential for at least 1 year after IMP infusion, even if he has undergone a successful vasectomy.
Exclusion Criteria
1. Patient has undergone a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤12 months prior to leukapheresis.
2. Patient has undergone a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning \>12 months, and suffers on chronic Graft-versus-Host Disease and/or is on systemic immune-suppressants.
3. Patient with diagnosis of MM
1. in first relapse following an autologous stem cell transplantation or
2. in second relapse that subsequently achieves a complete response that is considered being a candidate for an allogeneic stem cell transplantation, unless the patient explicitly denies undergoing an allogeneic stem cell transplantation.
4. Patient has received anti-CD38 and/or anti-SLAMF7 antibodies ≤8 weeks prior to leukapheresis.
5. Ongoing treatment with systemic immune-suppressants (e.g. systemic cyclosporine or systemic steroids at any dose).
(Note: Physiologic steroid replacement therapy, topical immune-suppressants as e.g. cyclosporine/tacrolimus eye drops and topical steroids are permitted.)
6. Echocardiogram with left ventricular ejection fraction \<45%.
7. Inadequate renal function defined by creatinine clearance (CrCl) ≤45 mL/min using Cockcroft-Gault equation.
8. Inadequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \>2.5 x upper limit of normal (ULN) and total bilirubin \>1.5 x ULN (unless due to Gilbert's syndrome and direct bilirubin is ≤1.5 x ULN; unless due to intrahepatic myeloma lesions as demonstrated by MRI or positron emission tomography (PET)/computed tomography (CT) not older than 4 weeks prior to screening).
9. International ratio (INR) or partial thromboplastin time (PTT) \>1.5 x ULN, unless on a stable dose of anti-coagulant.
10. Evidence of human immunodeficiency virus (HIV) infection.
11. Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV), excluding
* Patients who are hepatitis B surface antigen negative and HBV viral DNA negative
* Patients who had hepatitis B but have received an antiviral treatment and show non-detectable viral DNA for 6 months
* Patients who are seropositive because of hepatitis B virus vaccine
* Patients with known HBV infection but undetectable HBV viral load and on anti-viral therapy to prevent HBV reactivation.
12. Seropositive for and with active viral infection with hepatitis C virus (HCV), excluding
\- Patients who had hepatitis C but had received an antiviral treatment and show no detectable HCV viral RNA for 6 months.
13. Seropositive for syphilis on treponema pallidum hemagglutination test, excluding
\- Patients with negative treponema pallidum antibody absorption test result
14. Patients with active infection (e.g. asymptomatic and symptomatic severe acute respiratory syndrome coronavirus 2 \[SARS-CoV-2\] infection) or other serious medical or psychiatric disorder on investigators decision.
15. Pregnant or lactating women.
16. Current or previous (within 30 days of enrollment) treatment with another IMP.
17. Known abuse of alcohol, drugs, or medicinal products.
18. Employees of the sponsor, or employees or relatives of the investigator.
2. Patient has undergone a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning \>12 months, and suffers on chronic Graft-versus-Host Disease and/or is on systemic immune-suppressants.
3. Patient with diagnosis of MM
1. in first relapse following an autologous stem cell transplantation or
2. in second relapse that subsequently achieves a complete response that is considered being a candidate for an allogeneic stem cell transplantation, unless the patient explicitly denies undergoing an allogeneic stem cell transplantation.
4. Patient has received anti-CD38 and/or anti-SLAMF7 antibodies ≤8 weeks prior to leukapheresis.
5. Ongoing treatment with systemic immune-suppressants (e.g. systemic cyclosporine or systemic steroids at any dose).
(Note: Physiologic steroid replacement therapy, topical immune-suppressants as e.g. cyclosporine/tacrolimus eye drops and topical steroids are permitted.)
6. Echocardiogram with left ventricular ejection fraction \<45%.
7. Inadequate renal function defined by creatinine clearance (CrCl) ≤45 mL/min using Cockcroft-Gault equation.
8. Inadequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \>2.5 x upper limit of normal (ULN) and total bilirubin \>1.5 x ULN (unless due to Gilbert's syndrome and direct bilirubin is ≤1.5 x ULN; unless due to intrahepatic myeloma lesions as demonstrated by MRI or positron emission tomography (PET)/computed tomography (CT) not older than 4 weeks prior to screening).
9. International ratio (INR) or partial thromboplastin time (PTT) \>1.5 x ULN, unless on a stable dose of anti-coagulant.
10. Evidence of human immunodeficiency virus (HIV) infection.
11. Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV), excluding
* Patients who are hepatitis B surface antigen negative and HBV viral DNA negative
* Patients who had hepatitis B but have received an antiviral treatment and show non-detectable viral DNA for 6 months
* Patients who are seropositive because of hepatitis B virus vaccine
* Patients with known HBV infection but undetectable HBV viral load and on anti-viral therapy to prevent HBV reactivation.
12. Seropositive for and with active viral infection with hepatitis C virus (HCV), excluding
\- Patients who had hepatitis C but had received an antiviral treatment and show no detectable HCV viral RNA for 6 months.
13. Seropositive for syphilis on treponema pallidum hemagglutination test, excluding
\- Patients with negative treponema pallidum antibody absorption test result
14. Patients with active infection (e.g. asymptomatic and symptomatic severe acute respiratory syndrome coronavirus 2 \[SARS-CoV-2\] infection) or other serious medical or psychiatric disorder on investigators decision.
15. Pregnant or lactating women.
16. Current or previous (within 30 days of enrollment) treatment with another IMP.
17. Known abuse of alcohol, drugs, or medicinal products.
18. Employees of the sponsor, or employees or relatives of the investigator.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Union
OTHER
Sponsor Role
collaborator
Wuerzburg University Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Prof. Michael Hudecek
Role: STUDY_DIRECTOR
University Hospital Wuerzburg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Universitaire de Lille
Lille, , France
Site Status
Early Clinical Trial Unit University Hospital Wuerzburg
Würzburg, , Germany
Site Status
Clinical Trials Unit, Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
France
Germany
Spain
Related Links
Access external resources that provide additional context or updates about the study.
https://www.caramba-cart.eu/
CARAMBA project homepage
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-001264-30
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CARAMBA-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
NCT02302495
COMPLETED
PHASE2
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
NCT00445068
TERMINATED
PHASE2
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
NCT01775553
COMPLETED
PHASE2
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
NCT07200102
NOT_YET_RECRUITING
PHASE1
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
NCT03168100
WITHDRAWN
PHASE2
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
NCT03464916
COMPLETED
PHASE1
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
NCT06179888
RECRUITING
PHASE2
Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT01842308
COMPLETED
PHASE1/PHASE2
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
NCT04309981
UNKNOWN
PHASE1/PHASE2
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
NCT03915184
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma
NCT04065308
UNKNOWN
PHASE2
Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma
NCT01792102
UNKNOWN
PHASE1/PHASE2
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
NCT06140524
RECRUITING
PHASE2
Rituximab in Treating Patients With Multiple Myeloma
NCT00003554
COMPLETED
PHASE2
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
NCT06183489
RECRUITING
PHASE2
Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients
NCT02514239
COMPLETED
PHASE1
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT04975399
TERMINATED
PHASE1
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
NCT01949532
COMPLETED
PHASE1
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
NCT00477815
COMPLETED
PHASE1
Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe
NCT03091127
COMPLETED
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
NCT03489525
COMPLETED
PHASE1
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
NCT04933539
ACTIVE_NOT_RECRUITING
PHASE2
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma
NCT04000282
COMPLETED
PHASE1
Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant
NCT05982275
NOT_YET_RECRUITING
PHASE1/PHASE2